Replimune Group (NASDAQ:REPL) Given “Underweight” Rating at JPMorgan Chase & Co.

JPMorgan Chase & Co. reissued their underweight rating on shares of Replimune Group (NASDAQ:REPL) in a research report released on Monday morning, Marketbeat Ratings reports.

A number of other research firms also recently issued reports on REPL. Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday. Wedbush raised their price target on Replimune Group from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. Six research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $4.63.

Replimune Group Trading Down 64.3%

REPL opened at $1.70 on Monday. Replimune Group has a one year low of $1.50 and a one year high of $13.24. The company has a market cap of $140.37 million, a P/E ratio of -0.49 and a beta of 0.74. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The business’s 50-day simple moving average is $7.41 and its 200-day simple moving average is $7.94.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.08. As a group, equities research analysts expect that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the sale, the insider directly owned 151,588 shares of the company’s stock, valued at $1,214,219.88. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Institutional Trading of Replimune Group

Hedge funds have recently modified their holdings of the business. ProShare Advisors LLC raised its holdings in Replimune Group by 10.3% during the fourth quarter. ProShare Advisors LLC now owns 16,116 shares of the company’s stock worth $157,000 after purchasing an additional 1,505 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Replimune Group by 4.7% during the third quarter. JPMorgan Chase & Co. now owns 38,016 shares of the company’s stock worth $159,000 after purchasing an additional 1,712 shares during the last quarter. Ballentine Partners LLC raised its holdings in Replimune Group by 7.8% during the fourth quarter. Ballentine Partners LLC now owns 23,665 shares of the company’s stock worth $230,000 after purchasing an additional 1,721 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the last quarter. Finally, NEOS Investment Management LLC raised its holdings in Replimune Group by 5.0% during the third quarter. NEOS Investment Management LLC now owns 42,966 shares of the company’s stock worth $180,000 after purchasing an additional 2,060 shares during the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Company response — Replimune’s executive chairman publicly called the FDA decision “unfair” and discussed next steps in a TV interview; management tone suggests they will contest or seek clarification with the agency. Replimune co-founder calls FDA rejection ‘unfair’
• Neutral Sentiment: Market mechanics — Trading on REPL was temporarily halted (LULD pause) during the sell-off as the market digested the CRL. (Intraday regulatory pause)
• Neutral Sentiment: Industry analysis — A PharmTech piece reviews lessons from the RP1 CRL for other developers; useful context but does not change Replimune’s immediate financials. What Pharma Developers Can Learn From RP1’s Rejection
• Negative Sentiment: Regulatory setback — The FDA issued a CRL for RP1’s Biologics License Application for advanced melanoma, delaying approval and forcing Replimune to address agency deficiencies before any potential approval. FDA Issues CRL to Replimune for RP1 BLA
• Negative Sentiment: Second CRL / program risk — Coverage notes this is a second CRL for RP1, increasing uncertainty about the regulatory path and timing for any approval or label; that uncertainty undermines near-term revenue and valuation expectations. Replimune Gets Second FDA CRL
• Negative Sentiment: Market reaction — Major outlets report REPL plunged to an all-time low on the news, with heavy trading and a dramatic drop in market value. Street sours on Replimune
• Negative Sentiment: Cost actions — Reports indicate Replimune is planning layoffs after the FDA decision, signaling management expects reduced near-term operating activity and is cutting burn. Replimune plans layoffs after FDA rejects cancer therapy
• Negative Sentiment: Analyst reaction — Multiple firms cut ratings and slashed price targets (downgrades and lower PTs from Jefferies, BMO, Wedbush, Leerink, JPMorgan, HC Wainwright, Piper and others), reflecting reduced probability of near-term upside. FDA Rejection Sparks Questions On Replimune Drug Approval Path

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.